Farallon Capital Management LLC trimmed its stake in Horizon Pharma PLC (NASDAQ:HZNP) by 68.9% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 745,000 shares of the biopharmaceutical company’s stock after selling 1,650,000 shares during the quarter. Farallon Capital Management LLC owned approximately 0.46% of Horizon Pharma PLC worth $8,843,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of HZNP. Profund Advisors LLC grew its stake in Horizon Pharma PLC by 0.8% in the first quarter. Profund Advisors LLC now owns 13,508 shares of the biopharmaceutical company’s stock valued at $200,000 after purchasing an additional 112 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of Horizon Pharma PLC by 12.6% during the 1st quarter. Wells Fargo & Company MN now owns 498,787 shares of the biopharmaceutical company’s stock worth $7,372,000 after acquiring an additional 55,678 shares during the period. US Bancorp DE boosted its stake in shares of Horizon Pharma PLC by 1.2% during the 1st quarter. US Bancorp DE now owns 32,050 shares of the biopharmaceutical company’s stock worth $473,000 after acquiring an additional 368 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Horizon Pharma PLC by 3.1% during the 1st quarter. Bank of New York Mellon Corp now owns 764,571 shares of the biopharmaceutical company’s stock worth $11,300,000 after acquiring an additional 22,918 shares during the period. Finally, Swiss National Bank boosted its stake in shares of Horizon Pharma PLC by 1.6% during the 1st quarter. Swiss National Bank now owns 239,056 shares of the biopharmaceutical company’s stock worth $3,533,000 after acquiring an additional 3,700 shares during the period. Hedge funds and other institutional investors own 82.30% of the company’s stock.

Horizon Pharma PLC (NASDAQ HZNP) traded up 1.12% during mid-day trading on Friday, reaching $12.68. The company had a trading volume of 2,645,825 shares. The stock’s market capitalization is $2.07 billion. Horizon Pharma PLC has a one year low of $9.45 and a one year high of $21.98. The company’s 50-day moving average is $12.81 and its 200-day moving average is $12.94.

Horizon Pharma PLC (NASDAQ:HZNP) last announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.29. Horizon Pharma PLC had a positive return on equity of 22.85% and a negative net margin of 42.40%. The business had revenue of $289.51 million during the quarter, compared to analyst estimates of $237.01 million. During the same period in the prior year, the company earned $0.56 earnings per share. Horizon Pharma PLC’s revenue was up 12.5% compared to the same quarter last year. Equities research analysts anticipate that Horizon Pharma PLC will post $1.07 earnings per share for the current year.

HZNP has been the subject of several research analyst reports. Cantor Fitzgerald initiated coverage on Horizon Pharma PLC in a research note on Friday, June 16th. They set an “overweight” rating and a $13.00 target price for the company. ValuEngine downgraded Horizon Pharma PLC from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Piper Jaffray Companies set a $17.00 target price on Horizon Pharma PLC and gave the stock a “buy” rating in a research note on Tuesday, July 25th. Mizuho reiterated a “hold” rating and set a $12.00 target price (up from $9.00) on shares of Horizon Pharma PLC in a research note on Monday, August 28th. Finally, BidaskClub upgraded Horizon Pharma PLC from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. Five research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $18.00.

TRADEMARK VIOLATION WARNING: This story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.thecerbatgem.com/2017/09/30/farallon-capital-management-llc-has-8-84-million-holdings-in-horizon-pharma-plc-hznp.html.

About Horizon Pharma PLC

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Institutional Ownership by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)

Receive News & Stock Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related stocks with our FREE daily email newsletter.